Skip to main content
. 2020 Dec 17;59(1):e01649-20. doi: 10.1128/JCM.01649-20

TABLE 4.

Disk diffusion performance characteristics compared to broth microdilutiona

Organism(s) No. of isolates % (no.) with agreement or error
30-μg HardyDisks (FDA cleared)
30-μg MASTDISCS (RUO)
CLSI
FDAb (n = 73)
EUCAST
CLSI
FDAb
EUCAST
CA mE ME VME CA mE ME VME CA ME VME CA mE ME VME CA mE ME VME CA ME VME
Carbapenem-resistant Enterobacterales 58 91 (53) 9 (5) 0 0 84 (49) 16 (9) 0 0 88 (51) 17 (7) 0 88 (51) 12 (7) 0 86 (50) 14 (8) 0 0 90 (52) 14 (6) 0
    Carbapenemase-producing CRE 26 88 (23) 12 (3) 0 0 81 (21) 19 (5) 0 0 88 (23) 12 (3) 0 88 (23) 12 (3) 0 0 81 (21) 19 (5) 0 0 92 (24) 8 (2) 0
    Non-carbapenemase-producing CRE 32 94 (30) 6 (2) 0 0 88 (28) 12 (4) 0 0 88 (28) 12 (4) 0 88 (28) 12 (4) 0 0 91 (29) 9 (3) 0 0 88 (28) 12 (4) 0
Citrobacter freundii complex 2 50 (1) 50 (1) 0 0 50 (1) 50 (1) 0 0 50 (1) 100 (1) 0 50 (1) 50 (1) 0 0 50 (1) 50 (1) 0 0 50 (1) 100 (1) 0
Enterobacter cloacae complex 15 93 (14) 7 (1) 0 0 80 (12) 20 (3) 0 0 87 (13) 25 (2) 0 87 (12) 13 (2) 0 0 87 (13) 13 (2) 0 93 (14) 7 (1) 0
Escherichia coli 15 100 (15) 0 0 0 100 (15) 0 0 0 80 (12) 20 (3) 0 100 (15) 0 0 0 100 (15) 0 0 0 87 (13) 13 (2) 0
Klebsiella aerogenes 2 100 (2) 0 0 0 100 (2) 0 0 0 100 (2) 0 0 100 (2) 0 0 0 100 (2) 0 0 0 100 (2) 0 0
Klebsiella oxytoca 6 83 (5) 17 (1) 0 0 83 (5) 17 (1) 0 0 83 (5) 17 (1) 0 100 (6) 0 0 0 83 (5) 17 (1) 0 0 83 (5) 17 (1) 0
Klebsiella pneumoniae 15 87 (13) 13 (2) 0 0 73 (11) 27 (4) 0 0 100 (15) 0 0 73 (11) 27 (4) 0 0 73 (11) 27 (4) 0 0 83 (14) 7 (1) 0
Serratia marcescens 3 100 (3) 0 0 0 100 (3) 0 0 0 100 (3) 0 0 100 (3) 0 0 0 100 (3) 0 0 0 100 (3) 0 0
Non-glucose-fermenting Gram-negative bacilli 39 85 (33) 8 (3) 12 (3) 0 36 (5) 64 (9) 0 0 79 (31) 15 (4) 31 (4) 85 (33) 15 (6) 0 0 50 (7) 43 (6) 0 25 (1) 90 (35) 8 (2) 15 (2)
Pseudomonas aeruginosa 14 93 (13) 7 (1) 0 0 36 (5) 64 (9) 0 0 79 (11) 14 (2) 25 (1) 86 (12) 14 (2) 0 0 50 (7) 43 (6) 0 25 (1) 86 (12) 10 (1) 25 (1)
Acinetobacter baumannii complex 14 64 (9) 14 (2) 25 (3) 0 64 (9) 20 (2) 33 (3) 71 (10) 29 (4) 0 0 86 (12)c 20 (1)c 11 (1)c
Stenotrophomonas maltophilia 11 100 (11) 0 0 0 100 (11) 0 0 100 (11) 0 0 0 100 (11)c 0 0
All isolates 97 89 (86) 8 (8) 3 (3) 0 75 (54) 25 (18) 0 85 (82) 17 (11) 12 (4) 87 (84) 13 (13) 0 0 79 (57) 19 (14) 0 20 (1) 90 (87) 13 (8) 12 (4)
a

CRE, carbapenem-resistant Enterobacterales; FDA, U.S. Food and Drug Administration; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; S, susceptible; I, intermediate; R, resistant; RUO, research use only.

b

Breakpoints used for this analysis were prior to the 28 September 2020 update. The FDA breakpoints for the Enterobacterales (listed as Enterobacteriaceae on the FDA website) are specific for E. coli, K. pneumoniae, P. mirabilis, and E. cloacae complex. However, we used the breakpoints to interpret all Enterobacterales results in this study.

c

EUCAST provided disk correlates associated with the susceptible PK-PD breakpoint for A. baumannii and S. maltophilia. Although the PK-PD breakpoint for S is set at ≤2 μg/ml, there were no S. maltophilia isolates tested by EUCAST with MICs of >0.5 μg/ml. Thus, the disk correlate for S. maltophilia is for isolates with MICs of ≤0.5 μg/ml.